Scarica l'app Stockscreener
1.86
5.10%
-0.10
Dopo l'orario di chiusura:
1.87
0.01
+0.54%
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock - Yahoo Finance
Conferencia de resultados del 2T de 2026 de Karyopharm (KPTI): foco en la sNDA de selinexor y la liquidez - TradingKey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc.KPTI - YCharts
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript - AOL.com
KPTI Stock Price and Chart — NASDAQ:KPTI - TradingView
Why Is KPTI Stock Down 69% After-Hours Today? - Stocktwits
Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40 - simplywall.st
RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap - Stock Titan
Karyopharm Therapeutics (KPTI): Commodore Capital now reports 0.0% ownership - Stock Titan
KPTI|Karyopharm Therapeutics Inc|Price:2.015|Chg%:+0.025 - TradingKey
Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Karyopharm (KPTI) Ergebniskonferenz Q2 2026: Fokus auf Selinexor-sNDA und Liquidität - TradingKey
Karyopharm Therapeutics Inc (KPTI) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ... - Yahoo! Finance Canada
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highl - GuruFocus
It's crunch time for Karyopharm as company faces potential default next month - Fierce Pharma
Karyopharm Therapeutics has cash to last only into next month - The Business Journals
Karyopharm Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August By Investing.com - Investing.com Australia
Karyopharm Therapeutics Q2 2026 Earnings Call Transcript - marketbeat.com
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August - Investing.com
Karyopharm Q2 2026 slides: myelofibrosis data shines amid cash crunch - Investing.com
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
KPTI: Selinexor sNDA for myelofibrosis advances amid strong data, stable sales, and liquidity focus - TradingView
Earnings call transcript: Karyopharm Q2 2026 loss widens as cash pressure mounts - Investing.com
Karyopharm Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) 2026-08-13 - Seeking Alpha
Form 8K Karyopharm Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026 - marketscreener.com
Is Karyopharm Therapeutics Inc (KPTI) Undervalued at 64.1%? Q2 E - GuruFocus
Karyopharm Therapeutics Inc. Q2 2026: Revenue $33.4M, Net loss $67M, EPS $(2.32) — 10-Q Summary - TradingView
Karyopharm Therapeutics: Q2 Earnings Snapshot - Barchart.com
Karyopharm Reports $33.4 Million Q2 Revenue and $67 Million Net Loss - Quiver Quantitative
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission - Karyopharm
BRIEF-Karyopharm Therapeutics Q2 Net Income USD -67.023 Million - TradingView
Adage Capital reports 1.54M Karyopharm (KPTI) shares, a 6.78% stake - Stock Titan
Karyopharm Therapeutics Inc Stock Short Interest Rises to 33.51% - Quiver Quantitative
Goldman Sachs Group (KPTI) discloses 6.3% beneficial stake in Karyopharm - Stock Titan
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a shareEarnings Preview - TradingView
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 - Karyopharm
Karyopharm’s Aug. 13 results call will include slides online - Stock Titan
Karyopharm Therapeutics (KPTI) Drops 7.6% to $1.96, Testing Key Support at $1.86Mutual Fund Flow - vinanet.vn
Myelofibrosis Combo Advances as Karyopharm Preps August sNDA - Streetwise Reports
Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC) and Karyopharm Therapeutics (KPTI) - The Globe and Mail
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Weekly Recap: XPORT-EC-042 misses PFS endpoint and SENTRY sNDA reports SVR35 - TradingView
KPTI Stock Crashes As Trial Failure Triggers Legal Scrutiny - StocksToTrade
KPTI Stock Collapses As Trial Failure Triggers Downgrades And Legal Scrutiny - StocksToTrade
Low coffers, failed endometrial cancer trial: Karyopharm down 72% - bioworld.com
Jefferies Initiates Karyopharm Therapeutics(KPTI.US) With Buy Rating, Announces Target Price $11 - moomoo.com
Why is Karyopharm Therapeutics stock collapsing over 60% today? By Investing.com - Investing.com Canada
KPTI Looks 18.2% Overvalued on GF Value™ Amid Unprofitable Statu - GuruFocus
Karyopharm Therapeutics reports Phase 3 XPORT-EC-042 misses PFS; plans myelofibrosis sNDA - TradingView
Karyopharm plans selinexor-ruxolitinib combination filing for myelofibrosis accelerated approval - AllSci
Karyopharm endometrial cancer trial misses primary endpoint By Investing.com - Investing.com Nigeria
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):